Randomized phase II trial of erlotinib (E) plus high-dose celecoxib (HD-C) or placebo (P) in advanced non-small cell lung cancer.
Karen L. Reckamp
Consultant or Advisory Role - Genentech; Tragara Pharmaceuticals
Honoraria - Genentech
Research Funding - Astellas Pharma; Pfizer
Marianna Koczywas
No relevant relationships to disclose
Mihaela C. Cristea
No relevant relationships to disclose
Jonathan Dowell
Research Funding - Genentech
Brian Gardner
No relevant relationships to disclose
Ginger L Milne
No relevant relationships to disclose
Robert A. Figlin
No relevant relationships to disclose
Robert M. Elashoff
No relevant relationships to disclose
Steven M. Dubinett
Consultant or Advisory Role - Tragara Pharmaceuticals